Charles River Laboratories International (CRL) R&D Expense: History & Chart

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$272.90-5.45 (-1.96%)

Delayed quote: Sep 10, 2026, 2:10 PM EDT

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

Research & Development Expenses

The latest quarterly R&D expense is $0. Research and Development (R&D) expenses represent the costs incurred by a company in developing new products, services, or processes.

SG&A Expense|Operating Margin|Revenue|Net Income|Income Statement

R&D Expense

CRL R&D Expense

$0.00

Reported quarterly R&D expense; no daily interpolation. Q2 FY2026 (2026-06-27): $0.00.

Current R&D Expense

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly R&D Expense History

Period	R&D Expense	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-27	$0	N/A	N/A
Q1 FY2026Period end 2026-03-28	$0	N/A	N/A
Q4 FY2025Period end 2025-12-27	$0	N/A	N/A
Q3 FY2025Period end 2025-09-27	$0	N/A	N/A
Q2 FY2025Period end 2025-06-28	$0	N/A	N/A
Q1 FY2025Period end 2025-03-29	$0	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-28	$0	N/A	N/A
Q2 FY2024Period end 2024-06-29	$0	N/A	N/A
Q1 FY2024Period end 2024-03-30	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-09-30	$0	N/A	N/A
Q2 FY2023Period end 2023-07-01	$0	N/A	N/A
Q1 FY2023Period end 2023-04-01	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A
Q3 FY2022Period end 2022-09-24	$0	N/A	N/A
Q2 FY2022Period end 2022-06-25	$0	N/A	N/A
Q1 FY2022Period end 2022-03-26	$0	N/A	N/A
Q4 FY2021Period end 2021-12-31	$0	N/A	N/A
Q3 FY2021Period end 2021-09-25	$0	N/A	N/A
Q2 FY2021Period end 2021-06-26	$0	N/A	N/A
Q1 FY2021Period end 2021-03-27	$0	N/A	N/A
Q4 FY2020Period end 2020-12-31	$0	N/A	N/A
Q3 FY2020Period end 2020-09-26	$0	N/A	N/A
Q2 FY2020Period end 2020-06-27	$0	N/A	N/A
Q1 FY2020Period end 2020-03-28	$0	N/A	N/A
Q4 FY2019Period end 2019-12-31	$0	N/A	N/A
Q3 FY2019Period end 2019-09-28	$0	N/A	N/A
Q2 FY2019Period end 2019-06-29	$0	N/A	N/A
Q1 FY2019Period end 2019-03-30	$0	N/A	N/A
Q4 FY2018Period end 2018-12-31	$0	N/A	N/A
Q3 FY2018Period end 2018-09-29	$0	N/A	N/A
Q2 FY2018Period end 2018-06-30	$0	N/A	N/A
Q1 FY2018Period end 2018-03-31	$0	N/A	N/A
Q4 FY2017Period end 2017-12-31	$0	N/A	N/A
Q3 FY2017Period end 2017-09-30	$0	N/A	N/A
Q2 FY2017Period end 2017-07-01	$0	N/A	N/A
Q1 FY2017Period end 2017-04-01	$0	N/A	N/A
Q4 FY2016Period end 2016-12-31	$0	N/A	N/A
Q3 FY2016Period end 2016-09-24	$0	N/A	N/A
Q2 FY2016Period end 2016-06-25	$0	N/A	N/A
Q1 FY2016Period end 2016-03-26	$0	N/A	N/A
Q4 FY2015Period end 2015-12-31	$0	N/A	N/A
Q3 FY2015Period end 2015-09-26	$0	N/A	N/A
Q2 FY2015Period end 2015-06-27	$0	N/A	N/A
Q1 FY2015Period end 2015-03-28	$0	N/A	N/A
Q4 FY2014Period end 2014-12-31	$0	N/A	N/A
Q3 FY2014Period end 2014-09-27	$0	N/A	N/A
Q2 FY2014Period end 2014-06-28	$0	N/A	N/A
Q1 FY2014Period end 2014-03-29	$0	N/A	N/A
Q4 FY2013Period end 2013-12-31	$0	N/A	N/A
Q3 FY2013Period end 2013-09-28	$0	N/A	N/A
Q2 FY2013Period end 2013-06-29	$0	N/A	N/A
Q1 FY2013Period end 2013-03-30	$0	N/A	N/A
Q4 FY2012Period end 2012-12-31	$0	N/A	N/A
Q3 FY2012Period end 2012-09-29	$0	N/A	N/A
Q2 FY2012Period end 2012-06-30	$0	N/A	N/A
Q1 FY2012Period end 2012-03-31	$0	N/A	N/A
Q4 FY2011Period end 2011-12-31	$0	N/A	N/A
Q3 FY2011Period end 2011-09-24	$0	N/A	N/A
Q2 FY2011Period end 2011-06-25	$0	N/A	N/A
Q1 FY2011Period end 2011-03-26	$0	N/A	N/A
Q4 FY2010Period end 2010-12-31	$0	N/A	N/A
Q3 FY2010Period end 2010-09-25	$0	N/A	N/A
Q2 FY2010Period end 2010-06-26	$0	N/A	N/A
Q1 FY2010Period end 2010-03-27	$0	N/A	N/A
Q4 FY2009Period end 2009-12-31	$0	N/A	N/A
Q3 FY2009Period end 2009-09-26	$0	N/A	N/A
Q2 FY2009Period end 2009-06-27	$0	N/A	N/A
Q1 FY2009Period end 2009-03-28	$0	N/A	N/A
Q4 FY2008Period end 2008-12-31	$0	N/A	N/A
Q3 FY2008Period end 2008-09-27	$0	N/A	N/A
Q2 FY2008Period end 2008-06-28	$0	N/A	N/A
Q1 FY2008Period end 2008-03-29	$0	N/A	N/A
Q4 FY2007Period end 2007-12-31	$0	N/A	N/A
Q3 FY2007Period end 2007-09-29	$0	N/A	N/A
Q2 FY2007Period end 2007-06-30	$0	N/A	N/A
Q1 FY2007Period end 2007-03-31	$0	N/A	N/A
Q4 FY2006Period end 2006-12-31	$0	N/A	N/A
Q3 FY2006Period end 2006-09-30	$0	N/A	N/A
Q2 FY2006Period end 2006-07-01	$0	N/A	N/A
Q1 FY2006Period end 2006-04-01	$0	N/A	N/A
Q4 FY2005Period end 2005-12-31	$0	N/A	N/A
Q3 FY2005Period end 2005-09-24	$0	N/A	N/A
Q2 FY2005Period end 2005-06-25	$0	N/A	N/A
Q1 FY2005Period end 2005-03-26	$0	N/A	N/A
Q4 FY2004Period end 2004-12-31	$0	N/A	N/A
Q3 FY2004Period end 2004-09-25	$0	N/A	N/A
Q2 FY2004Period end 2004-06-26	$0	N/A	N/A
Q1 FY2004Period end 2004-03-27	$0	N/A	N/A
Q4 FY2003Period end 2003-12-31	$0	N/A	N/A
Q3 FY2003Period end 2003-09-27	$0	N/A	N/A
Q2 FY2003Period end 2003-06-28	$0	N/A	N/A
Q1 FY2003Period end 2003-03-29	$0	N/A	N/A
Q4 FY2002Period end 2002-12-31	$0	N/A	N/A
Q3 FY2002Period end 2002-09-28	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 27, 2026